2026, Number S1
<< Back Next >>
Rev Mex Anest 2026; 49 (S1)
Psychedelics in geriatrics: new horizons for pain and palliative care
Flores-Vargas A
Language: Spanish
References: 5
Page: 67-68
PDF size: 712.71 Kb.
Text Extraction
No abstract.
REFERENCES
Carhart-Harris RL, Goodwin GM. The therapeutic potential ofpsychedelic drugs: past, present and future. Neuropsychopharmacology. 2017;42:2105-2113.
Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin producessubstantial and sustained decreases in depression and anxiety inpatients with life-threatening cancer: A randomized double-blind trial.J Psychopharmacol. 2016;30:1181-1197.
Ross S, Bossis A, Guss J, et al. Rapid and sustained symptomreduction following psilocybin treatment for anxiety and depression inpatients with life-threatening cancer. Journal of Psychopharmacology.2016;30:1165-1180.
Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264-355.
Reiche S, Hermle L, Gutwinski S, et al. Serotonergic hallucinogens inthe treatment of anxiety and depression in patients suffering from a lifethreateningdisease: A systematic review. Prog NeuropsychopharmacolBiol Psychiatry. 2018;81:1-10.
Full text